Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Effective population size

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    94 result(s) found for: Effective population size. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2015-002669-45 Sponsor Protocol Number: ICL-23-ABSSSI1 Start Date*: 2016-02-18
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002687-16 Sponsor Protocol Number: ICL-24-ABSSSI2 Start Date*: 2016-05-05
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) PT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003415-22 Sponsor Protocol Number: AP-W-CLI-2018-8 Start Date*: 2019-03-22
    Sponsor Name:Aurealis Oy
    Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers
    Medical condition: Diabetic foot ulcers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001096-73 Sponsor Protocol Number: MIV-711-202 Start Date*: 2016-09-13
    Sponsor Name:Medivir AB
    Full Title: An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis
    Medical condition: Knee Join Osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000574-40 Sponsor Protocol Number: PSP-CoQ10 Start Date*: 2006-04-24
    Sponsor Name:Kompetenznetz Parkinson e.V.
    Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
    Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004902-82 Sponsor Protocol Number: BO28407 Start Date*: 2014-01-13
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III TRIAL COMPARING TRASTUZUMAB PLUS PERTUZUMAB PLUS A TAXANE FOLLOWING ANTHRACYCLINES VERSUS TRASTUZUMAB EMTANSINE PLUS PERTUZUMAB FOLLOWING ANTHRACYCL...
    Medical condition: HER2-positive operable primary breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) CZ (Completed) ES (Temporarily Halted) NO (Completed) BE (Prematurely Ended) SE (Prematurely Ended) PL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-001498-63 Sponsor Protocol Number: BIO101-CL05 Start Date*: 2020-07-22
    Sponsor Name:Biophytis S.A.
    Full Title: Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...
    Medical condition: Confirmed infection with SARS-CoV-2 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10047465 Viral infections NEC HLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-001815-21 Sponsor Protocol Number: ABH_EB-001 Start Date*: 2013-01-18
    Sponsor Name:Shire Regenerative Medicine, Inc.
    Full Title: A Multicenter, Prospective, Randomized, Open-label, Intra-patient Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated with General...
    Medical condition: Epidermolysis bullosa
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002500-21 Sponsor Protocol Number: Apollo01 Start Date*: 2023-04-11
    Sponsor Name:LUMC
    Full Title: Neo-adjuvant Pembrolizumab in vulvar squamous cell carcinoma: a clinical proof-of-concept study.
    Medical condition: Vulvar squamous cell carcinoma (VSCC) Clinically diagnosed FIGO I-III primary VSCC patients to be treated with surgery with curative intent
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000342-60 Sponsor Protocol Number: 190280 Start Date*: 2016-06-21
    Sponsor Name:Norfolk and Norwich University Hospital
    Full Title: Fatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate
    Medical condition: Sarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10039486 Sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000065-16 Sponsor Protocol Number: DS102A-07-CV1 Start Date*: 2020-08-11
    Sponsor Name:Afimmune Ltd.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients with Hypertriglyceridemia and Type 2 Diab...
    Medical condition: Hypertriglyceridemia and Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005655-16 Sponsor Protocol Number: Regard-CrC_2012 Start Date*: 2013-07-03
    Sponsor Name:Institut Jules Bordet
    Full Title: Regorafenib Assessment in Refractory advanced Colorectal cancer
    Medical condition: Advanced refractory colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003205-66 Sponsor Protocol Number: MedOPP293 Start Date*: 2022-01-17
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2)
    Medical condition: HER2-Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) IT (Trial now transitioned) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014263-40 Sponsor Protocol Number: MEL01 Start Date*: 2009-12-14
    Sponsor Name:Penwest Pharmaceuticals Co.
    Full Title: A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 day, Two-arm, Parallel Group Study of A0001 in Patients with the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitoch...
    Medical condition: A3243G mitochondrial DNA point mutation and evidence of impaired mitochondrial function
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000916-75 Sponsor Protocol Number: REC-DUT-002 Start Date*: 2018-06-07
    Sponsor Name:RECARDIO Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
    Medical condition: Acute myocardial infarction, acute myocardial ischemia, STEMI ST elevation myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) BE (Completed) NL (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003980-21 Sponsor Protocol Number: REX-001-005 Start Date*: 2021-08-31
    Sponsor Name:Rexgenero Limited
    Full Title: The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Ulcers in Subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placeb...
    Medical condition: Critical Limb Ischemia in patients with Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10077142 Limb ischemia LLT
    20.0 100000004866 10058069 Critical limb ischemia LLT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted) AT (Completed) NL (Completed) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) LV (Prematurely Ended) LT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003644-23 Sponsor Protocol Number: PTK0796-ABSI-1108 Start Date*: 2015-07-02
    Sponsor Name:Paratek Pharma LLC
    Full Title: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adult Subjects with Acute Bacterial Skin and Skin Str...
    Medical condition: Acute Bacterial Skin and Skin Structure Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) ES (Completed) PL (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012437-30 Sponsor Protocol Number: BUS‐2009/01 Start Date*: 2010-06-17
    Sponsor Name:Skånes University Hospital
    Full Title: Clofarabine based remission induction followed by haploidentical stem cell transplantation in children with refractory hematological malignancies
    Medical condition: Therapy resitant leukemia in children and young adults
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001967-35 Sponsor Protocol Number: CALCIDEB2016 Start Date*: 2016-07-19
    Sponsor Name:Universitätsklinik für Dermatologie, Paracelsus medizinische Privatuniversität Salzburg
    Full Title: A double-blind, placebo-controlled cross-over study to assess the efficacy of topical calcipotriol (Psorcutan®-ointment containing 0.05 µg/g calcipotriol) to improve wound healing in dystrophic epi...
    Medical condition: Subjects with dystrophic epidermolysis bullosa (DEB) with a known mutation in the type VII collagen gene.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002026-20 Sponsor Protocol Number: CT7001-001 Start Date*: 2017-10-31
    Sponsor Name:Carrick Therapeutics
    Full Title: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malign...
    Medical condition: Module 1A: All solid malignancies Module 1B: Solid malignancies, potentially including TNBC, SCLC, CRPC, ovarian cancer patients, and other appropriate cancer indications. Module 1B-1 (TNBC):...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 11:00:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA